Download PDF
Int J Angiol 2015; 24(02): 121-126
DOI: 10.1055/s-0034-1396900
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

How to Treat Obstructions in Patients with Hypertrophic Cardiomyopathy

Josef Veselka
1   Department of Cardiology, Motol University Hospital, Prague, Czech Republic
› Author Affiliations
Further Information

Publication History

Publication Date:
14 January 2015 (online)

    Permissions and Reprints

Abstract

Hypertrophic cardiomyopathy (HCM) is characterized by the presence of increased thickness of the left ventricular wall that is not solely explained by abnormal loading conditions. Two-thirds of the patients with HCM have an obstruction in the left ventricle after provocation or even while at rest. This obstruction is associated with more symptoms and a worse prognosis. The two main therapeutic approaches for treating a left ventricular obstruction are alcohol septal ablation and surgical myectomy. Both these techniques are discussed in this article. Currently, the final decision concerning the optimal invasive therapy for patients with obstructive HCM must be individualized to each patient depending on his/her wishes and expectations, way of life, age, heart morphology, and hemodynamics, as well as the experience of the treating center.

Keywords

alcohol septal ablation - surgical myectomy - hypertrophic cardiomyopathy

Note

This work was supported by a grant from the Ministry of Health of the Czech Republic NT/11401–5/2011.


 

  • References

  • 1 Gersh BJ, Maron BJ, Bonow RO , et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124 (24) e783-e831
    CrossrefPubMedGoogle Scholar
  • 2 Elliott PM, Anastasakis A, Borger MA , et al; Authors/Task Force members; Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39) 2733-2779
    CrossrefPubMedGoogle Scholar
  • 3 Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J 2011; 32 (9) 1059-1064
    CrossrefPubMedGoogle Scholar
  • 4 Anastasakis A, Theopistou A, Rigopoulos A , et al. Sudden cardiac death: investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort. Hellenic J Cardiol 2013; 54 (4) 281-288
    PubMedGoogle Scholar
  • 5 Maron BJ, Rowin EJ, Casey SA , et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >= 60 years of age. Circulation 2013; 127 (5) 585-593
    CrossrefPubMedGoogle Scholar
  • 6 Zemánek D, Tomasov P, Homolová S, Linhartová K, Veselka J. Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy. Eur J Echocardiogr 2011; 12 (9) 684-687
    CrossrefPubMedGoogle Scholar
  • 7 Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature. Med Sci Monit 2007; 13 (4) RA62-RA68
    PubMedGoogle Scholar
  • 8 Veselka J, Lawrenz T, Stellbrink C , et al. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol 2013; 29 (11) 1415-1421
    CrossrefPubMedGoogle Scholar
  • 9 Veselka J, Lawrenz T, Stellbrink C , et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study. Catheter Cardiovasc Interv 2014; 84 (1) 101-107
    CrossrefPubMedGoogle Scholar
  • 10 Ball W, Ivanov J, Rakowski H , et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 2011; 58 (22) 2313-2321
    CrossrefPubMedGoogle Scholar
  • 11 Watkins H, McKenna WJ. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46 (3) 477-479
    CrossrefPubMedGoogle Scholar
  • 12 Kirklin JW, Ellis Jr FH. Surgical relief of diffuse subvalvular aortic stenosis. Circulation 1961; 24: 739-742
    CrossrefPubMedGoogle Scholar
  • 13 Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 1961; 154: 181-189
    CrossrefPubMedGoogle Scholar
  • 14 Ommen SR, Maron BJ, Olivotto I , et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46 (3) 470-476
    Google Scholar
  • 15 Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg 2010; 140 (2) 317-324
    Google Scholar
  • 16 Desai MY, Bhonsale A, Smedira NG , et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 2013; 128 (3) 209-216
    CrossrefPubMedGoogle Scholar
  • 17 Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381 (9862) 242-255
    Google Scholar
  • 18 Panaich SS, Badheka AO, Chothani A , et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample 1998–2010). Am J Cardiol 2014; 114 (9) 1390-1395
    CrossrefPubMedGoogle Scholar
  • 19 Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346 (8969) 211-214
    CrossrefPubMedGoogle Scholar
  • 20 Kuhn HJ. The history of alcohol septal ablation. Cardiovasc Revasc Med 2010; 11 (4) 260-261
    PubMedGoogle Scholar
  • 21 Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesař D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005; 95 (5) 675-678
    CrossrefPubMedGoogle Scholar
  • 22 Veselka J, Zemánek D, Tomašov P, Homolová S, Adlová R, Tesař D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv 2010; 75 (4) 546-550
    PubMedGoogle Scholar
  • 23 Veselka J, Tomašov P, Zemánek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol 2011; 27 (6) 763-767
    CrossrefPubMedGoogle Scholar
  • 24 Kuhn H, Lawrenz T, Lieder F , et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10.  year experience. Clin Res Cardiol 2008; 97 (4) 234-243
    CrossrefPubMedGoogle Scholar
  • 25 Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 2007; 96 (12) 864-873
    CrossrefPubMedGoogle Scholar
  • 26 Veselka J, Zemánek D, Tomašov P, Duchonová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels 2009; 24 (1) 27-31
    CrossrefPubMedGoogle Scholar
  • 27 Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J 2014; 35 (30) 2040-2045
    CrossrefPubMedGoogle Scholar
  • 28 Jensen MK, Havndrup O, Hassager C , et al. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy. Scand Cardiovasc J 2011; 45 (3) 153-160
    CrossrefPubMedGoogle Scholar
  • 29 Sorajja P, Ommen SR, Holmes Jr DR , et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012; 126 (20) 2374-2380
    CrossrefPubMedGoogle Scholar
  • 30 Jensen MK, Prinz C, Horstkotte D , et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 2013; 99 (14) 1012-1017
    CrossrefPubMedGoogle Scholar